Search | Clinical Trials Finder

Conditions: Pneumococcal Infections
Interventions: V114, Prevnar 13™, PNEUMOVAX™23; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 1,515 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 38
States / cities: Chinle, Arizona • Fort Defiance, Arizona • Glendale, Arizona + 34 more

Conditions: Neoplasms, Prostate
Interventions: Dutasteride, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years to 75 Years · Male only
Enrollment: 8,231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 297
States / cities: Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 236 more

Conditions: Cheek Wrinkles
Interventions: Sculptra Aesthetic new dilution; Device
Lead sponsor: Galderma R&D; Industry
Eligibility: 21 Years and older
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 13
States / cities: Scottsdale, Arizona • Encino, California • Redondo Beach, California + 9 more

Conditions: Malaria
Interventions: Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01), GSK Biologicals' malaria vaccine 257049 (2 doses), GSK Biologicals' malaria vaccine 257049 (3 doses), Sporozoite challenge; Biological · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Major Depressive Disorder
Interventions: Levomilnacipran ER, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 724 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 38
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 33 more

Conditions: Diabetic Neuropathies
Interventions: SPM 927; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 654 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: RTP, North Carolina

Conditions: Actinic Keratosis
Interventions: Imiquimod cream, Placebo cream; Drug
Lead sponsor: Graceway Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 26
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Encino, California + 22 more

Conditions: Major Upper or Lower Abdominal Surgery
Interventions: Oral sufentanil, Placebo; Drug
Lead sponsor: Talphera, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Mydriasis
Interventions: Tropicamide/Phenylephrine ophthalmic solution (TR/PE), Placebo; Drug
Lead sponsor: Eyenovia Inc.; Industry
Eligibility: Not listed
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Austin, Texas • San Antonio, Texas

Conditions: Acinetobacter Baumannii Infection
Interventions: ETX2514SUL; Drug
Lead sponsor: Entasis Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Lakewood, Colorado • Miami, Florida • Minneapolis, Minnesota

Conditions: Fibromyalgia
Interventions: TNX-102 SL, Placebo SL Tablet; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 33 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Selexipag, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 43
States / cities: Mobile, Alabama • Tucson, Arizona • La Jolla, California + 32 more

Conditions: Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention
Interventions: RSV preF-based Vaccine, Placebo; Biological · Drug
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 60 Years and older
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 11
States / cities: Long Beach, California • DeLand, Florida • Miami Lakes, Florida + 7 more

Conditions: Hepatitis C
Interventions: TD-6450, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Asthma
Interventions: AMG 761, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Denver, Colorado • Miami, Florida

Conditions: RSV Infection
Interventions: Clesrovimab, Palivizumab, Placebo; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: Up to 1 Year
Enrollment: 1,003 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 29
States / cities: Long Beach, California • Orange, California • Aurora, Colorado + 22 more

Conditions: Staphylococcal Vaccine
Interventions: Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine, Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 3,450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 234
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 89 more

Conditions: Influenza
Interventions: NanoFlu, Fluzone HD - Day 0, Fluzone HD - Day 21, Saline - Day 21; Biological · Other
Lead sponsor: Novavax; Industry
Eligibility: 60 Years and older
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Raleigh, North Carolina • Rocky Mount, North Carolina • Statesville, North Carolina

Conditions: Asthma
Interventions: AZD8630, Placebo, Inhaler; Drug · Device
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 45
States / cities: Mesa, Arizona • Huntington Beach, California • La Mesa, California + 41 more

Conditions: Asthma
Interventions: MEDI528 0.3 mg/kg, MEDI528 1 mg/kg, MEDI528 3 mg/kg, PLACEBO; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Denver, Colorado • North Dartmouth, Massachusetts • Minneapolis, Minnesota + 3 more

Conditions: Occlusive Stroke
Interventions: Asahi Chikai Black 18 neurovascular guidewire; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Ovarian Cancer
Interventions: Farletuzumab, Carboplatin, Taxane, Farletuzumab-matched placebo; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 110
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 91 more

Conditions: Hypercholesterolemia, Dyslipidemia
Interventions: Placebo, Statin, PF-04950615 (RN316), Satin; Biological · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 38
States / cities: Tustin, California • Walnut Creek, California • Clearwater, Florida + 25 more

Conditions: Hyperphosphatemia
Interventions: Tenapanor, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 32
States / cities: Huntsville, Alabama • Riverside, California • Denver, Colorado + 28 more

Search by objective public record fields.

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk

Safety and Effectiveness of Sculptra Aesthetic for Correction of Cheek Wrinkles

Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy

Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)

A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery

Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation

Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects

A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia

Selexipag (ACT-293987) in Pulmonary Arterial Hypertension

A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older

TD-6450 SAD and MAD in Healthy Subjects

AMG 761 in Adults With Asthma

Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation

Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma

SURE 18 Registry -Asahi Chikai Black 18 in LVO Stroke

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins

An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)